← 홈

폐암 (NSCLC) · HER2

12개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 12개
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 106상태 RECRUITING
ADCBBiologicTheRas, Inc., dPhase 2

mFOLFOX6 (mFOLFOX6)

Non-Small Cell Lung Cancer; NSCLC · HER2

#HER2#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 63.64%임상시험 71상태 RECRUITING
ADCBiologicEMD Serono Research & Developme…Phase 3

M7824 (M7824)

Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 62.5%임상시험 43상태 DISCONTINUED
ADCBiologicBeijing Biostar Pharmaceuticals…Phase 2

Utidelone (Utidelone)

Non-small Cell Lung Cancer Patients with Brain Metastases · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 36상태 RECRUITING
ADCBiologicstaleShanghai Junshi Bioscience Co.,…Phase 2

JS207 (JS207)

Non-squamous Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleEnliven TherapeuticsPhase 1

ELVN-002 (ELVN-002)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 2상태 RECRUITING
ADCBiologicstaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Furmonertinib, 1L)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
ADCBiologicstaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Furmonertinib, 2L+)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 1상태 ACTIVE
AntibodystaleSun Yat-sen UniversityPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, RC48+Tislelizumab+carboplatin)

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, pertuzumab + trastuzumab + docetaxel)

Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Stage III · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 ACTIVE
ADCBiologicstaleCancer Institute and Hospital, …Phase 2

Almonertinib/Furmonertinib/Osimertinib (third-generation EGFR TKIs, third-generation EGFR TKIs (Almonertinib/Furmonertinib/Osimertinib))

Non Small Cell Lung Cancer; ERBB2 Mutation-Related Tumors · EGFR

#EGFR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 1상태 RECRUITING